Cancer patients treated with immune checkpoint inhibitors (ICIs) are susceptible to a broad
and variable array of immune‐related adverse events (irAEs). With increasing clinical use of …

In recent years, the indications for immunotherapy in cancer treatment have been
expanding. The increased risk of cancer in young people, coupled with the fact that many …

Autoimmune toxicity occurs in up to 60% of patients treated with immune checkpoint inhibitor
(ICI) therapy for cancer and represents an increasing clinical challenge for expanding the …

Central hypothyroidism (CH) is characterized by decreased thyroid hormone production due
to insufficient stimulation of an otherwise normal thyroid gland by TSH. In patients with …

Hypophysitis, a rare inflammatory disorder of the pituitary gland, has seen an uptick in
reported cases in recent years. Our objective is to summarize the most recent research on …

Simple Summary Immune-related adverse events (irAEs) are one of the most common
complications after cancer treatment caused by immune checkpoint inhibitors (ICIs). We …

Hypoprolactinaemia is an endocrinopathy which is typically encountered as part of a
combined pituitary hormone deficiency picture. The vast majority of genetic causes identified …

Introduction Hypophysitis is reported in 8.5%–14% of patients receiving combination
immune checkpoint inhibition (cICI) but can be a diagnostic challenge. This study aimed to …

Introduction Almost one-quarter of immune checkpoint inhibitor (ICI) recipients experience
sicca syndrome, while Sjögren's disease (SjD) is estimated at 0.3-2.5%, possibly …

Introduction The aim of this study was to define functional and anatomical pituitary disease
at the time of presentation following immune checkpoint inhibitor (ICI) therapy and to …